title: Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
abstract: OBJECTIVE
  To evaluate the subfoveal choroidal thickness after treatment of central serous chorioretinopathy (CSC) visualized by enhanced depth imaging spectral-domain optical coherence tomography (EDI OCT) and indocyanine green angiography (ICGA).
  
  
  METHODS
  Retrospective, comparative series.
  
  
  METHODS
  Twenty patients (20 eyes).
  
  
  METHODS
  The subfoveal choroidal thickness and height of the serous retinal detachment before and after treatment was measured using EDI OCT. Areas of choroidal vascular hyperpermeability were visualized with ICGA. Eyes with classic CSC were treated with laser photocoagulation (LP), whereas eyes with chronic CSC, which are not amenable to LP, were treated with half-dose verteporfin photodynamic therapy (PDT).
  
  
  METHODS
  Change in choroidal thickness and height of the serous retinal detachment after treatment.
  
  
  RESULTS
  There were 12 eyes in the LP group and 8 eyes in the PDT group. The serous subretinal fluid resolved in both groups after treatment. In the LP group, the mean choroidal thickness was 345+/-127 microm at baseline and 340+/-124 microm at 4 weeks, a difference that was not significant (P = 0.2). The mean choroidal thickness in the PDT group increased significantly from 389+/-106 microm at baseline to 462+/-124 microm (P = 0.008) by 2 days after treatment, and then reduced rapidly to 360+/-100 microm (P = 0.001) at 1 week and 330+/-103 microm (P<0.001) after 4 weeks as compared with baseline. Indocyanine green angiography showed decreased hyperpermeability in the PDT group after treatment.
  
  
  CONCLUSIONS
  The subretinal fluid resolved in both disease groups; however, the choroidal thickness and hyperpermeability seen during ICGA was reduced after PDT. These findings suggest that PDT reduces the choroidal vascular hyperpermeability seen in CSC and may work by a different mechanism than LP.
authors.affiliation: Department of Ophthalmology, Fukushima Medical University School of Medicine, Fukushima, Japan. imaruko@fmu.ac.jp
authors.forename: Ichiro
authors.initials: I
authors.lastname: Maruko
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Iida
authors.forename: Yukinori
authors.initials: Y
authors.lastname: Sugano
authors.forename: Akira
authors.initials: A
authors.lastname: Ojima
authors.forename: Masashi
authors.initials: M
authors.lastname: Ogasawara
authors.forename: Richard F
authors.initials: RF
authors.lastname: Spaide
mesh_terms: D000328:Adult; D000368:Aged; D002199:Capillary Permeability; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*; D002829:Choroid / Q000098:blood supply / Q000473:pathology*; D004396:Coloring Agents; D005122:Exudates and Transudates; D005260:Female; D005451:Fluorescein Angiography; D005584:Fovea Centralis; D006801:Humans; D007208:Indocyanine Green; D017075:Laser Coagulation; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D004396:Coloring Agents; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D007208:Indocyanine Green